Precision, accuracy, and resolution-Dose selection of oral anticancer agents.

about

Precision, accuracy, and resolution-Dose selection of oral anticancer agents.

Item

http://www.wikidata.org/entity/Q54467809

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Precision, accuracy, and resolution-Dose selection of oral anticancer agents.

@en

Precision, accuracy, and resolution-Dose selection of oral anticancer agents.

@nl

type

Item

label

Precision, accuracy, and resolution-Dose selection of oral anticancer agents.

@en

Precision, accuracy, and resolution-Dose selection of oral anticancer agents.

@nl

prefLabel

Precision, accuracy, and resolution-Dose selection of oral anticancer agents.

@en

Precision, accuracy, and resolution-Dose selection of oral anticancer agents.

@nl

P1476

Precision, accuracy, and resolution-Dose selection of oral anticancer agents.

@en

P2093

R Donald Harvey

http://www.w3.org/2001/XMLSchema#string

Tyler J Beardslee

http://www.w3.org/2001/XMLSchema#string

P2860

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Erlotinib in previously treated non-small-cell lung cancer

Epidermal growth factor receptor mutations in lung cancer

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.

"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.

Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers

Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).

Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug-drug interactions.

P31

scholarly article

editorial

P356

10.1002/CNCR.30273

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2016-08-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27526184

http://www.w3.org/2001/XMLSchema#string